Variable | Total (n = 116) | Vancomycin (n = 54) | Teicoplanin (n = 62) | p value |
---|---|---|---|---|
Male | 92 (79.3%) | 39 (72.2%) | 53 (85.5%) | 0.079 |
Age (years) | 61.4 ± 13.1 | 67.7 ± 12.9 | 67.2 ± 13.4 | 0.842 |
Body mass index (kg/m2) | 21.3 ± 4.3 | 20.5 ± 4.6 | 22.1 ± 3.9 | 0.050 |
Coexisting condition | ||||
 DM | 33 (28.4%) | 14 (25.9%) | 19 (30.6%) | 0.574 |
 HTN | 46 (39.7%) | 19 (35.2%) | 27 (43.5%) | 0.358 |
 Pulmonary disease | 38 (32.8%) | 11 (20.4%) | 27 (43.5%) | 0.009 |
 Cardiovascular disease | 31 (26.7%) | 10 (18.5%) | 21 (33.9%) | 0.062 |
 Renal disease | 12 (10.3%) | 6 (11.1%) | 6 (9.7%) | 0.800 |
 Cerebrovascular disease | 31 (26.7%) | 21 (38.9%) | 10 (16.1%) | 0.006 |
 Liver diseasea | 10 (8.6%) | 3 (5.6%) | 7 (11.3%) | 0.334 |
 History of transplantationa | 10 (8.6%) | 9 (16.7%) | 1 (1.6%) | 0.006 |
 Malignancy | 0.288 | |||
  Solid | 33 (28.4%) | 14 (25.9%) | 19 (30.6%) |  |
  Hematologic | 10 (8.6%) | 7 (13.0%) | 3 (4.8%) |  |
 Recent chemotherapy | 26 (22.4%) | 11 (20.4%) | 15 (24.2%) | 0.622 |
 Recent radiotherapya | 6 (5.2%) | 3 (5.6%) | 3 (4.8%) | > 0.999 |
 Neurologic disease | 19 (16.4%) | 10 (18.5%) | 9 (14.5%) | 0.561 |
Type of pneumonia | 0.107 | |||
 CAP | 37(31.9%) | 17 (31.5%) | 20 (32.3%) |  |
 HAP | 37 (31.9%) | 22 (40.7%) | 15 (24.2%) |  |
 VAP | 42 (36.2%) | 15 (27.8%) | 27 (43.5%) |  |
Bacteremia | 20 (17.2%) | 10 (18.5%) | 10 (16.1%) | 0.734 |
MIC | Â | Â | Â | Â |
 Vancomycin |  |  |  | 0.569 |
  ≤ 0.5 | 1 (0.9%) | 0 (0.0%) | 1 (1.6%) |  |
  1 | 87 (75.0%) | 42 (77.8%) | 45 (72.6%) |  |
  2 | 28 (24.1%) | 12 (22.2%) | 16 (25.8%) |  |
 Teicoplanina |  |  |  | > 0.999 |
  ≤ 4 | 112 (96.6%) | 52 (96.3%) | 60 (96.8%) |  |
  8 | 4 (3.4%) | 2 (3.7%) | 2 (3.2%) |  |
Initial vital sign | Â | |||
 SBP | 121.5 ± 22.6 | 119.8 ± 21.3 | 123.0 ± 23.7 | 0.448 |
 DBP | 68.0 ± 13.9 | 67.1 ± 14.5 | 68.7 ± 13.4 | 0.517 |
 Pulse rate | 98.9 ± 21.4 | 99.8 ± 21.6 | 98.2 ± 21.5 | 0.699 |
 Body temperature | 37.2 ± 0.8 | 37.2 ± 0.8 | 37.2 ± 0.8 | 0.673 |
 Respiratory rateb | 22.3 ± 5.8 | 21.9 ± 6.0 | 22.7 ± 5.7 | 0.801 |
Mechanical ventilation | 70 (60.3%) | 30 (55.6%) | 40 (64.5%) | 0.325 |
Systemic steroids | 31 (26.7%) | 13 (24.1%) | 18 (29.0%) | 0.547 |
APACHE II scoreb | 13.5 ± 5.3 | 13.1 ± 5.4 | 13.9 ± 5.2 | 0.324 |
White blood cell counts | 11.9 ± 5.7 | 11.6 ± 5.6 | 12.1 ± 5.9 | 0.609 |
C-reactive proteinb | 11.0 ± 8.6 | 12.1 ± 7.9 | 10.1 ± 9.2 | 0.045 |
Procalcitonin (n = 79) b | 5.4 ± 19.1 | 1.5 ± 2.8 | 9.4 ± 26.6 | 0.367 |
Creatinineb | 1.2 ± 1.2 | 1.1 ± 1.2 | 1.3 ± 1.1 | 0.008 |
Vancomycin serum trough levels (µg/mL) | ||||
 Day 3 (n = 45) | n/a | 13.5 ± 8.1 | n/a |  |
 Day 6 (n = 34) | n/a | 20.4 ± 8.3 | n/a |  |
 Day 9 (n = 29) | n/a | 17.3 ± 4.7 | n/a |  |
Teicoplanin regimen | Â | |||
 High-dose regimen | n/a | n/a | 15 (24.2%) |  |
 Low-dose regimen | n/a | n/a | 47 (75.8%) |  |
Therapeutic duration, daysb | 14.7 ± 8.2 | 14.7 ± 9.1 | 14.7 ± 7.4 | 0.658 |